The modern pharmaceutical company has announced that it hopes to offer its vaccine against COVID-19 at a price of between $ 32 and $ 37 per dose, a “pandemic price”, which will depend on the volume requested by each country and hopes to guarantee its universal access.
Moderna’s vaccine produces “robust” immunity, according to study with primates
“We are working with governments around the world and with others to ensure that the vaccine is accessible regardless of the ability to pay,” Moderna CEO Stephane Bancel said in a call with investors.
The price will be lower for those countries that request large volumes of doses, said the company, who clarified that a “small” order, for which the price bracket announced today would apply, would be of the order of several million doses.
That price is above the $ 19.50 that Pfizer advanced for the vaccine that it develops together with the German BioNTech and that is, as in the case of Moderna, at the beginning of phase 3, the final stretch of clinical tests to certify its reliability and safety.
Moderna’s announcement took place in the presentation of the results for the second quarter of the year, in which the Massachusetts-based company multiplied its revenue by five to $ 66.4 million.
At the end of July, Moderna had already received $ 400 million in deposits to supply the mRNA-1273 vaccine, the distribution of which is already negotiating with several interested countries.
The US government has disbursed $ 483 million in April and another $ 472 million thereafter for the development of its vaccine.
Moderna collaborates with the National Institutes of Health (NIH) in the development and clinical trials of the mRNA.1273 vaccine, which uses messenger RNA technology and has shown promising results in the first tests with humans.